Skip to contentT
TELA Bio, Inc.
T
TELATELA Bio, Inc. Q1 2026 · 10-Q
Revenue$19.06M$19.06M+2.9% vs Q1 2025 Net Income-$12.27M-$12.27MN/M vs Q1 2025 EPS Diluted-$0.21-$0.21N/M vs Q1 2025 Gross Profit$12,520,000+0.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TELA Bio, Inc. · CIK 1561921 · Engraved from SEC EDGAR
Operating Cash Flow-$11,170,000N/M Free Cash Flowderived-$11,289,000N/M Margins · derivedGross margin65.7%−1.9 pt vs Q1 2025
Operating margin-55.2%+1.3 pt vs Q1 2025
Net margin-64.4%−3.6 pt vs Q1 2025
ended Mar 31, 2026 · filed May 13, 2026 · 43 d after period end